Journal Watch
- PDF / 118,837 Bytes
- 10 Pages / 583.276 x 792 pts Page_size
- 22 Downloads / 154 Views
UPDATE
© 2008 Adis Data Information BV. All rights reserved.
Journal Watch Contents 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29.
Waiting for Reimbursement of New Medicines in Canada: It’s Time for a Rethink . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 325 NICE’s 2008 Methods Guide: Sensible Consolidation or Opportunities Missed? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 325 NICE Guide to the Methods of Technology Appraisal: Pharmaceutical Industry Perspective . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 326 NICE Methodology for Technology Appraisals: Cutting Edge or Tried and Trusted? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 326 The NICE Cost-Effectiveness Threshold: What it is and What that Means . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 326 Estimating ‘Costs’ for Cost-Effectiveness Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 327 Use of Indirect and Mixed Treatment Comparisons for Technology Assessment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 327 Valuing Health States for Use in Cost-Effectiveness Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 327 Exploring Uncertainty in Cost-Effectiveness Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 327 Subgroups and Heterogeneity in Cost-Effectiveness Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 327 Biomarkers of Clinical Responsiveness in Brain Tumour Patients: Progress and Potential . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 328 Recognition of Genetic Factors Influencing the Progression of Hepatitis C: Potential for Personalized Therapy . . . . . . . . . . . . . . . 328 Biomarkers for Alzheimer Disease in Cerebrospinal Fluid, Urine and Blood . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 328 Cell-Based Influenza Vaccines: Progress to Date . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 329 Promising Newer Molecular-Targeted Therapies in Head and Neck Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 329 A Model for Decision Support in Signal Triage . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 329 Modelling Approaches: The Case of Schizophrenia . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Data Loading...
